Retraction Note to: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells (British Journal of Cancer, (2005), 92, 10, (1899-1905), 10.1038/sj.bjc.6602595);The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells

British Journal of Cancer

Volumn 92, Issue 10, 2005, Pages 1899-1905

  Mandal, M ^a   Kim, S ^a   Younes, M N ^a   Jasser, S A ^a   El Naggar, A K ^a   Mills, G B ^a   Myers, J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic thyroid cancer; Growth factors; KP372 1; Molecular therapy

Indexed keywords

KP 372 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; KP372 1; KP372-1; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; TETRAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; WESTERN BLOTTING; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; THYROID TUMOR;

APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TETRAZOLES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 19644387196     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/s41416-021-01299-9     Document Type: Erratum

References (24)

1. Bellacosa A, Testa JR, Staal SP, Tsichlis PN (1991) A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254: 274-277
2. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ (2002) Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997
3. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA (1994) The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene 9: 1661-1668
4. Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997
5. Coulonval K, Vandeput F, Stein RC, Kozma SC, Lamy F, Dumont JE (2000) Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J 348(Part 2): 351-358
6. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57: 4710-4713
7. Fagin JA (2002) Minireview: branded from the start - distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16: 903-911
8. Guo M, Joiakim A, Reiners Jr JJ (2000) Suppression of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Biochem Pharmacol 60: 635-642
9. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932
10. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092
11. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6: 880-886
12. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8-29
13. Kimura T, Dumont JE, Fusco A, Golstein J (1999) Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. Eur J Endocrinol 140: 94-103
14. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP (2001) Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22: 631-656
15. Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T (2002) Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogens 21: 5868-5876
16. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67
17. Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun SC, Kumar R (1996) Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signaling pathway. J Biol Chem 271: 30354-30359
18. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M (2002) Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591
19. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61: 6105-6111
20. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532
21. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M, Ringel MD (2001) Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 11: 339-351
22. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD (2004) Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41: 161-170
23. von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359: 487-491
24. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248